Clinical trials: Cancer Treatment
Metastatic Castration-resistant Prostate Cancer
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with any of the approved life-prolonging therapies: abiraterone 1000 mg daily plus prednisone…
- Trial name
- NCT04158245
- Testing
- 18F-fluciclovine PET Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Tulane University
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
The purpose of this study is to evaluate pidilizumab and its effect, bad and/or good, on the immune system in relation to its ability to fight cancer cells.
- Trial name
- NCT02530125
- Testing
- Laboratory Biomarker Analysis, Pidilizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00287989
- Testing
- Carboplatin, erlotinib hydrochloride, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
This phase II trial studies the side effects lirilumab and azacitidine and to see how well they work in treating patients with acute myeloid leukemia that has not responded to treatment or has returned after a period of…
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02399917
- Testing
- Azacitidine, Lirilumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00736450
- Testing
- oblimersen sodium, rituximab, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Nebraska
Advanced Clear Cell Renal Carcinoma
Vandetanib to Treat Advanced Kidney Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply it with nutrients and oxygen. Vandetanib (ZD6474) is an experimental drug that blocks certain proteins on the surface of tumor and blood…
- Trial name
- NCT01372813
- Testing
- vandetanib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Prostatic Neoplasms
Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Background: Some men with prostate cancer have their prostate glands removed. The cancer can still come back. Researchers want to know if receiving a vaccine before prostate removal surgery can lead to less recurrence.
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Neoplasms, Prostate
- Trial name
- NCT02153918
- Testing
- PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
COMbination of Bipolar Androgen Therapy and Nivolumab
Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Trial name
- COMBAT-CRPC (NCT03554317)
- Testing
- Testosterone cypionate, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy.
- Trial name
- HUDSON (NCT03334617)
- Testing
- Durvalumab, Danvatirsen, Ceralasertib
- Where
- 45 sites in United States, Austria and 6 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Malignant Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous…
- Trial name
- NCT00539591
- Testing
- Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- St. Jude Children's Research Hospital
Liver Cancer
Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Trial name
- NCT00293397
- Testing
- Drug-eluting beads loaded with doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Prostate Carcinoma
GET FIT Prostate: A Randomized Controlled Exercise Trial
The GET FIT Prostate trial (Group Exercise Training for Fall prevention and functional Improvements during and after Treatment for Prostate cancer) is a single-blind, parallel group, randomized controlled trial comparing - 1) tai…
- Trial name
- NCT03741335
- Testing
- Resistance Training, Stretching, Tai Chi
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- OHSU Knight Cancer Institute
Tobacco Use, Tobacco Smoking
Tobacco Cessation at FDNY
At the Fire Department of the City of New York (FDNY) World Trade Center Health Program, 36% of participants in the low dose computed tomography (LDCT) lung cancer screening program are current smokers, despite referral to the…
- Conditions
- Tobacco Use, Tobacco Smoking, Tobacco Use Cessation
- Trial name
- NCT05997225
- Testing
- opt out enrollment, tailored counseling, varenicline started prior to target quit date, opt in enrollment, non-tailored counseling, varenicline started prior to target quit date
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Neoplasms, Breast
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709618
- Testing
- Lapatinib, Vinorelbine
- Where
- 22 sites in United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer, Fallopian Tube Cancer
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- PanGem (NCT01296035)
- Testing
- Panitumumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Lymphoma
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- SELENE (NCT01974440)
- Testing
- Bendamustine, Rituximab, Cyclophosphamide
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 403 people
- Sponsor
- Janssen Research & Development, LLC
Follicular Lymphoma
Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1
The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.
- Trial name
- NCT02461290
- Testing
- Chemotherapy, Rituximab
- Where
- 6 sites in Serbia
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.